Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
109.3 USD | +1.64% | +2.59% | +74.36% |
05-23 | U.S. FDA advisers back approval for Guardant's cancer test | RE |
05-14 | Piper Sandler Adjusts Price Target on Natera to $120 From $110, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+74.36% | 13.2B | |
+17.86% | 82.59B | |
-28.99% | 69.86B | |
0.00% | 26.5B | |
+3.06% | 17.29B | |
-13.07% | 16.61B | |
+1.92% | 15.56B | |
+1.53% | 12.75B | |
+74.28% | 12.6B | |
+2.74% | 12.19B |
- Stock Market
- Equities
- NTRA Stock
- News Natera, Inc.
- UBS Boosts Price Target on Natera to $160 From $104, Keeps Buy Rating